Evaluating the anti-cancer activity of myricetin in the management of oral cancer using in silico analysis

Abstract

Myricetin has been examined in various types of human cancer cells. However, there have been very few studies on oral cancer. The aim of this research was to assess Myricetin's anticancer potential in oral cancer using in silico network analysis. The in silico analysis included the determination of drug-likeness prediction, prediction of common targets between oral cancer and myricetin, Protein-Protein Interactions (PPI), hub genes, top 10 associated pathways by Kyoto Encyclopaedia of Genes and Genomes (KEGG) pathway and Gene Ontology (GO), and molecular docking experiments. 22 common genes were obtained and were seen to be involved in the Ras signaling pathway, PI3K-Akt signaling pathway, chemical carcinogenesis-ROS, Pathways in cancer, and microRNAs in cancer. The most common genes involved in the top 10 pathways were AKT1, EGFR, and MET which were seen associated with the PI3K-Akt signaling pathway which may be the key pathway through which myricetin may aid in treating oral cancer. Molecular docking also indicated its drug-like activity against oral cancer having a high affinity for AKT1.

According to the findings, myricetin possesses anticancer effects and has the potential to be employed as a chemotherapy medication. The in silico approach applied in this study can serve as a paradigm for future research in the development of effective cancer treatments.